Highlights

  • Xenitra shares rose 20.00% to AUD 0.0030 on 2 June 2026, following the release of latest operational update.
  • The company has secured exclusive distribution rights for Biomiq Skincare across Greater China under a four-year agreement.
  • The arrangement includes minimum product offtake commitments totalling AUD 5 million over the initial contract period.
  • Biomiq becomes the second major Brand integrated into Xenitra’s OPAL tokenised sales ecosystem.
  • The planned product launch is targeted for August 2026.

Xenitra Limited (ASX:XEN) shares climbed 20.00% to AUD 0.0030 during the afternoon session on 2 June 2026 after the company announced a new exclusive distribution agreement for the Biomiq Skincare range across Greater China.

The agreement represents another step in Xenitra’s strategy of building a portfolio of consumer brands within its blockchain-enabled sales ecosystem. Under the arrangement, Xenitra will become the exclusive distributor of Biomiq products throughout Greater China under an initial four-year term that carries minimum purchase commitments of AUD 5 million.

The market appeared to react favourably to the announcement, which expands the company’s product offering and adds a second major consumer brand to its developing OPAL tokenised sales platform.

About Xenitra and Its Commercial Strategy

Xenitra operates in the fast-moving consumer goods (FMCG), nutraceutical, personal care and over-the-counter healthcare sectors. The company focuses on helping international brands enter Asian markets through a distribution network that combines traditional sales channels with blockchain-enabled technologies.

A central part of Xenitra’s strategy is the development of its OPAL tokenised sales ecosystem, a platform designed to connect brands, distributors and consumers through digital incentives, authentication tools and traceability features.

The company describes the platform as a commercial ecosystem capable of supporting multiple consumer brands while encouraging customer engagement and repeat purchases.

The Biomiq agreement follows the earlier addition of EZZ products to the ecosystem and further expands the range of products available through Xenitra’s distribution network.

Exclusive Greater China Rights Secured

The newly announced agreement has been signed with Servatus Ltd, the owner of the Biomiq skincare brand.

Under the arrangement, Xenitra's Wholly Owned Subsidiary, M Best Tax Free Pty Limited, has been appointed as the exclusive distributor of Biomiq products throughout Greater China.

The contract commenced on 2 June 2026 and has an initial term of four years.

Unless either party elects to terminate the arrangement under the agreement's notice provisions, the contract will automatically renew for successive three-year periods following the initial term.

The agreement grants Xenitra exclusive rights across all sales channels within the territory, providing the company with sole distribution access for the Biomiq product range in the Greater China market.

Management expects product launches under the agreement to begin from August 2026.

Minimum Offtake Commitments Total AUD 5 Million

One of the most notable commercial aspects of the agreement is the inclusion of minimum purchase commitments.

To maintain exclusive distribution rights, Xenitra must purchase a minimum value of Biomiq products over the four-year period.

The required annual purchase thresholds are structured as follows:

  • AUD 500,000 during the first year
  • AUD 1 million during the second year
  • AUD 1.5 million during the third year
  • AUD 2 million during the fourth year

Collectively, these commitments amount to AUD 5 million over the initial contract term.

The agreement provides Servatus with the ability to terminate Xenitra’s exclusive distribution rights if the required annual minimum purchases are not achieved.

Payment terms require 50% of invoice values to be paid upon receipt, with the remaining 50% payable within 75 days of invoice issuance.

These commercial arrangements provide a framework for the planned rollout of Biomiq products throughout Greater China over the coming years.

Biomiq Adds New Category Exposure

Biomiq specialises in skincare products designed to support skin health through microbiome-focused formulations.

The range currently includes more than 20 product lines and focuses on several skincare categories, including acne treatment and prevention, management of minor skin conditions and anti-ageing formulations.

According to Xenitra, the product range has experienced rapid growth in Australia since 2025, supported by Social Media-driven Marketing initiatives and online sales channels.

The company highlighted that Biomiq has developed products aimed at addressing acne-related conditions while also expanding into skincare products targeting menopause and perimenopause-related concerns.

Biomiq products are manufactured in Australia by Australian Biotherapeutics, which forms part of the broader Servatus Biopharmaceuticals Group.

The addition of the skincare range broadens the product categories available through Xenitra’s distribution platform and adds exposure to the personal care market.

Second Brand Added to OPAL Ecosystem

The Biomiq agreement also represents another step in the expansion of Xenitra’s OPAL ecosystem.

Management stated that Biomiq will become the second major brand integrated into the tokenised sales platform following the introduction of EZZ products earlier this year.

The OPAL ecosystem combines traditional distribution channels with blockchain-based features designed to support product authentication, traceability, customer loyalty and consumer engagement.

According to the company, the platform is intended to function as a self-reinforcing commercial model capable of accommodating multiple consumer brands.

By adding additional products and brands, Xenitra aims to increase activity across the ecosystem while creating more opportunities for customer participation and repeat purchasing.

The company believes the platform may offer particular benefits in international markets where product authenticity and Supply-chain transparency are important considerations.

Growing Sales Activity Supports Expansion Plans

In commentary accompanying the announcement, Xenitra highlighted recent progress across its commercial platform.

Management noted that sales generated through the tokenised ecosystem had approached AUD 1 million during the first six weeks following launch.

The company indicated that recurring purchases, customer engagement and social media-driven sales activity have contributed to early traction within the platform.

The addition of Biomiq is expected to expand the range of products available to consumers while supporting the broader objective of building a scalable multi-brand ecosystem.

Although commercial performance will ultimately depend on product Demand and execution, the agreement reflects Xenitra’s ongoing efforts to increase the number of brands participating within its sales network.

Governance and Related Party Considerations

The company also disclosed governance measures associated with the agreement.

Non-Executive Chairman Dr Anthony Noble serves as an executive director of Servatus and is also a non-executive director of Xenitra.

According to the company, Dr Noble did not participate in negotiations relating to the agreement and was absent from the approval process.

Xenitra stated that independent directors reviewed and approved the transaction on arm’s-length terms.

The company also noted that Dr Noble will not receive any additional financial benefit arising from the agreement beyond his existing salary and director remuneration arrangements.

Independent directors additionally assessed Servatus’ capacity to supply the contracted product volumes under the agreement.

What This Means for Investors

Xenitra’s latest announcement introduces a new commercial Partnership that expands its consumer product portfolio and broadens the reach of its OPAL tokenised sales ecosystem.

The exclusive four-year distribution agreement provides access to the Greater China market for the Biomiq skincare range and includes minimum purchase commitments totalling AUD 5 million across the initial contract term.

The addition of a second major brand to the ecosystem aligns with the company’s strategy of building a multi-brand distribution platform that combines traditional commerce with blockchain-enabled functionality.

Investors will likely monitor the planned August launch, future sales activity and the integration of Biomiq into the broader OPAL ecosystem as Xenitra continues to develop its commercial platform.